Approximately $500 billion worth of M&A deals are waiting to happen. We can help you tap into the right audience, tech due diligence, and healthcare intel and cut down the lag phase from search to go-to-market.
We are different, as our teams believe in end-to-end solutions for M&A firms and are largely based on the process lifecycle. The healthcare M&As Consulting Team helps our clients with intelligence gathering, strategy identification, and peer deal alerts. Our analysts can support you with therapeutic-specific content, tech-specific content, and tech penetration analysis, as well as market forecasts. At SGA, the life sciences & healthcare business insights team works in collaboration with the investment research team, which supports us with the required due diligence. Together as a team, we are unmatched and unstoppable.
M&A firms... Read More
Why SGA
Industry Leaders
SGA thrives by its brand promise Lifes Possible and is recognized as the trusted life sciences & healthcare business consulting and services provider company in the U.S.
12+ Languages
Multilingual capabilities include Mandarin, Cantonese, Korean, German, Spanish, Arabic, Bahasa, Hindi, Bengali, and English (U.S. & U.K.) experts (either in-house or partnerships).
Data-Driven Insights
With in-depth domain knowledge and proven capabilities of delivering monetizable insights, we deliver high-quality, efficient outputs.
End-To-End Solutioning
The in-house KOL capability of more than 700, along with in-house capabilities of primary market research, financial research, data analytics, engineering, IT, and ESG research and consulting, helps to present credible competitive information.
Whitepapers
Emergence of Novel Immune - Mediated Therapies
Immunotherapy has emerged as a promising treatment for cancer, with immune checkpoint inhibitors (ICIs) dominating the market. The market is projected to...
Whitepapers
Future Trends and Technological Advances in Vaccine and Disease Prevention
The introduction of vaccines for key diseases, such as meningococcal meningitis A, hepatitis E, and malaria, in recent years has helped to reduce mortality...
Whitepapers
Market Entry in 2023: Why Must You Also Look at Markets Other Than the US and Japan?
Due to dollar fluctuations and the likelihood of market recession, investors and manufacturers of medical devices and pharma are exploring new opportunities...
CASE STUDIES
We strongly believe in equal opportunity for all. Our research team consists of more females than males i.e., 55 % females, and consists of PhDs, M Pharms, D Pharms, Postgraduate in finance, Biotech postgraduates, and MBAs.
